SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Meta Expands AI Training With Employee Activity Tracking Tools 
LEXINGTON, Mass., March 28, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to attend and present at the Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20am ET at the Westin New York Grand Central Hotel in New York City.
A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company’s website at www.t2biosystems.com under Investors. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
